. home.aspx


Real-World Evidence is What Pharma Needs Now to Help Cure Lung Cancer

July 11, 2019

Non-Small Cell Lung Cancer (NSCLC) is a designation that accounts for more than 80 percent of lung cancers diagnosed, and it has emerged as a new hotspot for investment by pharma manufacturers. Globally, the NSCLC therapeutics market is expected to rise to a valuation of US $15.1 billion by 2023, with pharma giants like Novartis, Pfizer, AstraZeneca, BMS, Celgene, and Genentech actively working to bring new drugs to market. Moreover, more than 700 research organizations have at least one cancer therapy in late-stage development, with most of the largest pharmaceutical companies dedicating at least one-third of their late-stage research and development activity in oncology.